The FDA has accepted its first computational drug development tool, and C-Path has built a coalition to qualify the rest. The bottleneck in AI drug discovery is now evidence standards, not model accuracy.
In August 2026, GenBio AI and Arc Institute pushed biological AI from reading DNA to simulating a whole cell. The models are impressive; the data, the benchmarks and the GPU bill will decide who wins.
The EU's IRIS² secure-connectivity programme moved from plan to purchase order in September, with three primes taking the first €5 billion in awards. Its cost has risen from €6 billion to €15.6 billion, and first launches have slipped to 2029.
For sixty years the powered military exoskeleton died on the scale. Edgerun, a Y Combinator startup, says humanoid-robotics components finally make a ten-pound hip unit viable — and that the first profitable market may be mining and construction, not the infantry.
Yara's Sluiskil facility captures up to 800,000 tonnes of CO2 a year — half a percent of Dutch emissions — and ships it to Norway for burial 2.6 km beneath the seabed. The capture works; storage capacity is the bottleneck.
The FDA cleared the first myostatin inhibitor on 11 September 2026. ISEMBYLD is an add-on for SMA at about $310,000 a year — but the real asset is Phase 2 data showing it preserves muscle during GLP-1 weight loss.
AIUC raised a $40M Series A led by Ribbit Capital to push its AIUC-1 standard from AI agents to frontier models. The certification layer now covers agents from Cursor, ElevenLabs, Harvey and KPMG, provided buyers and insurers agree the mark means something.
France and the UAE are underwriting a $1B constellation that interprets its own imagery in orbit. The technical case is clear; the commercial case is not.